Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter Sells 1,000 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Garnreiter also recently made the following trade(s):

• On Monday, September 16th, Michael Garnreiter sold 1,000 shares of Axon Enterprise stock. The shares were sold at an average price of $380.99, for a total value of $380,990.00.

Axon Enterprise Trading Down 0.1 %

NASDAQ:AXON opened at $433.83 on Thursday. Axon Enterprise, Inc. has a 12 month low of $199.29 and a 12 month high of $440.89. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The firm’s 50 day moving average is $385.93 and its 200 day moving average is $330.03. The stock has a market capitalization of $32.78 billion, a PE ratio of 114.47, a price-to-earnings-growth ratio of 11.74 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the prior year, the firm earned $0.80 EPS. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. Sell-side analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXON. Avantax Advisory Services Inc. lifted its stake in shares of Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 40 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Axon Enterprise in the first quarter worth $931,000. Zurich Insurance Group Ltd FI grew its position in shares of Axon Enterprise by 1.9% in the second quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock valued at $60,324,000 after purchasing an additional 3,832 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Axon Enterprise by 14.8% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after purchasing an additional 22,013 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Axon Enterprise by 21.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after buying an additional 1,634 shares during the period. Institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on AXON. Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. JMP Securities upped their target price on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Barclays boosted their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Northland Securities raised their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.